Synergistic Attenuation of Myocardial Fibrosis in Spontaneously Hypertensive Rats by Joint Treatment With Benazepril and Candesartan

Benazepril, all angiotensin-converting enzyme inhibitor, and candesartan, all angiotensin receptor blocker, are common drugs for treating hypertension. This study aimed to investigate the enhanced attenuation of myocardial fibrosis in spontaneously hypertensive rats (SHRs) possibly induced by joint treatment with benazepril and candesartan and the possible involvement of transforming growth factor beta(1) (TGF-beta(1))-Smad signaling pathway SHRs were treated with benazepril at 10 mg.kg(-1).d(-1), candesartan at 4 mg.kg(-1).d(-1), and a combination of 2 drugs at half close, respectively, for 12 weeks. Echocardiography and histology indicated that joint treatment with 2 drugs more significantly inhibited myocardial fibrosis in SHRs than either monotherapy. as evidenced by the changes in cardiac structural parameters, ultrasonic integrated backscatters, collagen volume fraction, and perivascular collagen area. The collagen analyses further revealed that significant decreases in total collagen concentration, the ratio of collagen type I to type III and collagen cross-linking were found after the enhanced attenuation of myocardial fibrosis. Western blot analysis showed that the protein expression of TGF-beta(1) and Smad3 was significantly decreased after joint treatment with 2 drugs. We conclude that synergistic attenuation of myocardial fibrosis in SHRs is produced by combined Use of benazepril and candesartan possibly through the modulation of TGF-beta/Smad signaling proteins.